Opioid-Induced Constipation – Opportunity Analysis and Forecasts To 2017: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Opioid-Induced Constipation – Opportunity Analysis and Forecasts To 2017 in subject line and your contact details. The Opioid-Induced Constipation (OIC) is a new and rapidly establishing market currently dominated by OTC laxatives set to undergo substantial growth between 2012 and 2017. The main drivers of growth will be an increase in the diagnosed OIC population. This is fuelled by a relaxation of regulations regarding opioid treatment, particularly in the chronic non-cancer pain population. As a result opioid use has risen sharply in the last 15 years. Concurrently, there has been a rapid increase in patients experiencing OIC, with approximately 40-50% of chronic opioid users reporting symptoms. Traditionally, constipation has been treated with laxatives based on empirical research. However, the efficacy of laxatives to treat OIC is relatively poor and only provides adequate relief for approximately 50% of patients. Prior to 2008, the OIC market was desolate, with no approved pharmaceutical (non-laxative) treatment for this condition. There is currently a paucity of approved products, with heavy restrictions limiting their use for the majority of OIC sufferers. However, the OIC therapeutic market is set to enter an explosive period of growth over the five-year forecast period. This advance is catalyzed by a major shift in the OIC treatment algorithm with the entry of several highlytargeted, efficacious, orallyformulated drugs. The competitive landscape will continue to evolve over the forecast period. Scope
Overview of OIC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized OIC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast to 2017. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the OIC therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs Analysis of the current and future market competition in the global OIC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Complete report available at http://www.marketoptimizer.org/opportunityanalyzer-opioid-inducedconstipation-opportunity-analysis-and-forecasts-to-2017-event-driven-update.html . Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. Develop business strategies by understanding the trends shaping and driving the global OIC therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OIC therapeutics market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Track drug sales in the global OIC therapeutics market from 2012-2017. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Inquire for discount @ www.marketoptimizer.org/contacts/discount?rname=9793 . (Report price: Single user license- US$ 5995 ) List of Tables Table 1: Symptoms of Opioid-Induced Constipation 24 Table 2: Number of Cases of Opioid-Induced Constipation in the US, 2012-2017 35 Table 3: Number of Cases of Opioid-Induced Constipation in France, 2012-2017 38 Table 4: Number of Cases of Opioid-Induced Constipation in Germany, 2012-2017 41 Table 5: Number of Cases of Opioid-Induced Constipation in Italy, 2012-2017 44 Table 6: Number of Cases of Opioid-Induced Constipation in Spain, 2012-2017 47 Table 7: Number of Cases of Opioid-Induced Constipation in the UK, 2012-2017 50 Table 8: Total Number of Cases of Opioid-Induced Constipation Among Chronic Opioid Users in the 6MM, 2012-2017 51 Table 9: Commonly Prescribed and OTC Laxatives Used To Treat Opioid-Induced Constipation 53 Table 10: Leading Treatments for Opioid-Induced Constipation 57 Table 11: Product Profile – Relistor 59 Table 12: Relistor SWOT Analysis 64 Table 13: Product Profile – Targin 66 Buy a Copy of Report @ http://www.marketoptimizer.org/contacts/purchase?rname=9793 .
Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “OpioidInduced Constipation – Opportunity Analysis and Forecasts To 2017” report OR for any other market research and intelligence needs you may have for your business.